Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Bayer completes US filing for prostate cancer drug darolutamideBayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share XBayer completes US filing for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
Bayer takes control of Loxo duo as Lilly closes takeoverBayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share XBayer takes control of Loxo duo as Lilly closes takeoverhttps://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitrakvi (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
The devil’s in the e-detail: what HCPs really want from youOverview Communication; we all do it, it is a critical part of effective business practice and in this Share XThe devil’s in the e-detail: what HCPs really want from youhttps://pharmaphorum.com/digital/the-devils-in-the-e-detail-what-hcps-really-want-from-you/
Bayer applies artificial intelligence to its pharmacovigilance systemsBayer is looking to accelerate its patient safety data monitoring by using artificial intelligence in a move it Share XBayer applies artificial intelligence to its pharmacovigilance systemshttps://pharmaphorum.com/news/bayer-artificial-intelligence-pharmacovigilance/
Bayer plans filings for prostate cancer drug darolutamideBayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped Share XBayer plans filings for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-plans-filings-for-prostate-cancer-drug-darolutamide/
